A retrospective study evaluating long-term efficacy and safety of plasma-derived human C1-INH concentrate in french population of patients from COBRA registry

Trial Profile

A retrospective study evaluating long-term efficacy and safety of plasma-derived human C1-INH concentrate in french population of patients from COBRA registry

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Complement C1 inhibitor protein (Primary)
  • Indications Angioedema; Hereditary angioedema
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Mar 2017 New trial record
    • 06 Mar 2017 Results (n=16) assessing response to attack treatment in patients with drug-induced angioedema, presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 01 Mar 2017 Results published in the European Journal of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top